Environmental Finance Network Meeting of experts from Eastern Europe, Caucuses and Central Asia (EECCA). The meeting will be held on 22-23 February 2007 at the OECD Headquarters in Paris.
English, , 2,675kb
This article shows the possible opportunities and risks of nanotechnologies today.
The Wengen 2006 workshop took place from October 4-6, 2006, and brought together experts from the climate science, policy, and economics communities together with decision-makers from countries within the Alpine Arc.
Markets for many classes of recyclable materials are growing, but market failures and barriers are constraining some markets. This report presents the case for the use of 'industrial' policies which address such market failures and barriers.
This document provides information on current/planned activities related to the safety of manufactured nanomaterials in OECD countries. Information was provided as written reports by delegations who participated in the 1st Meeting of OECD's Working Party on Manufactured Nanomaterials.
The OECD Global Forum on Sustainable Development, in cooperation with the World Bank and Agence Française de Développement, will discuss how governments in developing countries can work with local private water companies to provide affordable safe water and basic sanitation.
English, , 1,659kb
Economic Aspects of Environmental Compliance Assurance - proceedings
Transport activity continues to cause large adverse impacts on the environment, human health and the economy. But is a negative impact of transport on the environment a necessary consequence of economic growth?
OECD Secretary-General Angel Gurría has welcomed the publication this week of the Stern Review to the UK government on the economic consequences of climate change. The report was compiled by Sir Nicholas Stern, former chief economist at the World Bank.
The main objectives of the workshop were: i) to discuss the history and evolution of the conceptual framework for the evaluation of transgenic plant products in the environment and OECD’s role in the development of that framework; ii) to discuss the current contribution of OECD’s Working Group for the Harmonization of Regulatory Oversight in Biotechnology to risk/ safety assessment practice; and iii) to discuss current risk assessment